India reported a 21% fall in tuberculosis incidence and a 25% drop in mortality between 2015 and 2024. The government spent over ₹6,763 crore in 2025-26 on TB and non-communicable disease initiatives, which may impact demand for affordable diagnostics and medicine providers.
India has recorded a significant improvement in public health outcomes, with tuberculosis incidence dropping by 21% and mortality falling by 25% between 2015 and 2024. Union Health Minister J.P. Nadda presented these figures in the Rajya Sabha, emphasizing that India’s progress in reducing TB cases outpaces the global average decline of 12% recorded during the same period. This shift is supported by enhanced efforts under the National Health Mission and the ongoing TB Mukt Bharat Abhiyaan, which prioritizes early screening and consistent treatment coverage.
Impact on Diagnostics and Treatment Data
Reporting efficiency has improved substantially, with TB case notifications rising from 25.52 lakh in 2023 to 26.37 lakh by 2025, according to data from the Ni-kshay portal. This trend suggests a more systematic approach to tracking and treating the disease. Increased focus on diagnostics, including chest X-rays and nucleic acid amplification tests, is central to the government’s current strategy. For investors, this shift toward broader population-based screening and centralized health monitoring programs indicates a sustained demand for diagnostic equipment and testing services across district-level health centers.
Non-Communicable Diseases and Medication Access
Beyond infectious diseases, the government is expanding its infrastructure for non-communicable diseases, such as diabetes and cancer. The National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) has established a vast network, including 770 district NCD clinics and over 500 day-care cancer centers. With over 2.29 crore diabetes cases reported between fiscal years 2023-24 and 2025-26, the scaling of this program highlights a shift toward decentralized care. The reduction in customs duties and GST on specific high-cost cancer medications, combined with the expansion of Pradhan Mantri Bhartiya Janaushadhi Pariyojana and AMRIT pharmacies, reflects a policy move aimed at lowering patient costs.
Government Spending and Future Monitorables
Total expenditure for TB elimination and non-communicable disease control programs reached ₹6,763.85 crore in 2025-26. As the government continues to allocate substantial funds toward these health mandates, the key monitorable for market participants will be the consistency of procurement orders for essential drugs and diagnostic kits. Investors may track future budgetary allocations and the pace at which state-run cancer institutes and district-level NCD clinics expand their operational capacity, as these factors directly influence the revenue visibility for companies participating in the domestic healthcare and pharmaceutical supply chain.